GB9827034D0 - Delivery formulation - Google Patents

Delivery formulation

Info

Publication number
GB9827034D0
GB9827034D0 GB9827034A GB9827034A GB9827034D0 GB 9827034 D0 GB9827034 D0 GB 9827034D0 GB 9827034 A GB9827034 A GB 9827034A GB 9827034 A GB9827034 A GB 9827034A GB 9827034 D0 GB9827034 D0 GB 9827034D0
Authority
GB
United Kingdom
Prior art keywords
matrix
dose form
delivery formulation
delivered
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB9827034A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victoria University of Manchester
University of Manchester
Original Assignee
Victoria University of Manchester
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victoria University of Manchester, University of Manchester filed Critical Victoria University of Manchester
Priority to GB9827034A priority Critical patent/GB9827034D0/en
Publication of GB9827034D0 publication Critical patent/GB9827034D0/en
Priority to AU18667/00A priority patent/AU1866700A/en
Priority to PCT/GB1999/004096 priority patent/WO2000033816A1/en
Ceased legal-status Critical Current

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A delivery formulation for administration to a mucous membrane and which is either mucoadhesive per se or becomes mucoadhesive on contact with a mucous membrane, said formulation comprising a particulate material to be delivered to or across the membrane in a matrix or dose form containing an amphiphilic substance. Prefered formulations in accordance with the invention comprise a matrix or dose form of the amphiphilic substance in a liquid crystal phase, the matrix or dose form incorporating the particulate material to be delivered.
GB9827034A 1998-12-10 1998-12-10 Delivery formulation Ceased GB9827034D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB9827034A GB9827034D0 (en) 1998-12-10 1998-12-10 Delivery formulation
AU18667/00A AU1866700A (en) 1998-12-10 1999-12-10 Formulation for delivery of particulate material to mucosal membranes
PCT/GB1999/004096 WO2000033816A1 (en) 1998-12-10 1999-12-10 Formulation for delivery of particulate material to mucosal membranes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9827034A GB9827034D0 (en) 1998-12-10 1998-12-10 Delivery formulation

Publications (1)

Publication Number Publication Date
GB9827034D0 true GB9827034D0 (en) 1999-02-03

Family

ID=10843876

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9827034A Ceased GB9827034D0 (en) 1998-12-10 1998-12-10 Delivery formulation

Country Status (3)

Country Link
AU (1) AU1866700A (en)
GB (1) GB9827034D0 (en)
WO (1) WO2000033816A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2060259E (en) 2001-11-01 2010-04-26 Spectrum Pharmaceuticals Inc Medical compositions for intravesical treatment of bladder cancer
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
KR100533460B1 (en) * 2002-07-20 2005-12-08 대화제약 주식회사 Mucoadhesive composition and formulation for solubilization of insoluble drugs and preparation method thereof
ES2545454T3 (en) * 2002-12-10 2015-09-11 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US20080305149A1 (en) * 2007-06-11 2008-12-11 Thomas Hirt Mucoadhesive vesicles for drug delivery
WO2012119838A1 (en) * 2011-03-04 2012-09-13 Unilever Nv Self-adhesive hard surface cleaning composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8310038D0 (en) * 1983-04-13 1983-05-18 Amersham Int Plc Technetium-99 labelled tin colloid
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
SE518578C2 (en) * 1994-06-15 2002-10-29 Gs Dev Ab Lipid-based composition
JP2857741B2 (en) * 1995-08-31 1999-02-17 佐賀大学長 Coated drug-encapsulated crosslinked chitosan composition, method for producing the same, and use as drug sustained release control system
CA2231273A1 (en) * 1995-10-12 1997-04-17 Lise Sylvest Nielsen A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface

Also Published As

Publication number Publication date
WO2000033816A1 (en) 2000-06-15
AU1866700A (en) 2000-06-26

Similar Documents

Publication Publication Date Title
CA2416383A1 (en) Solution-, dispersion- or emulsion-producing film dermatics
DE69520492T2 (en) LIQUID MEDICINAL PREPARATIONS CONTAINING THYROID HORMONES
EP0458894A4 (en) Lipid excipient for nasal delivery and topical application.
CA2045290A1 (en) Plaster with a high content of softening ingredients
AU6476496A (en) Novel formulations for transdermal delivery of pergolide
TR200100144T2 (en) Pharmaceutical aerosol formulation
GR3033301T3 (en) Medicament form for the delivery of active substances to wounds
ATE286725T1 (en) NEW ORAL MEDICINAL PREPARATIONS FOR RIVASTIGMINE WITH CONTROLLED RELEASE OF ACTIVE INGREDIENTS
FI971776A (en) Compounds and compositions for the administration of active substances
MXPA01007411A (en) Compositions and methods for mucosal delivery.
AU7315496A (en) Delivery of biologically active polypeptides
IL108234A0 (en) Pharmaceutical composition containing galanthamine
NZ501950A (en) Medicinal compositions for application to mucosa
ATE353009T1 (en) PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH SOFT GELATIN FORMULATIONS
DK0800386T3 (en) Transdermal system for simultaneous administration of several active substances
NZ320237A (en) Stable pharmaceutical forms of administration containing parathormone
GR3019479T3 (en) Pharmaceutical compositions for transmucosal delivery of peptides.
CA2271944A1 (en) Formulation for electrically assisted delivery of lidocaine and epinephrine
ATE173923T1 (en) ORAL LIQUID MEDICINAL PREPARATION CONTAINING 2-(4-ISOBUTYLPHENYL)PROPIONIC ACID
GB9827034D0 (en) Delivery formulation
AU2002215944A1 (en) Film for active ingredients dermal and transdermal administration
CA2294448A1 (en) Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
WO2000027430A3 (en) Composition consisting of influenza virus surface proteins and dispensing device
SE9403389D0 (en) Pharmaceutical composition containing derivatives of sex hormones
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)